EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of RIPK1 or RIPK3 kinase activity post ischemia-reperfusion reduces the development of chronic kidney injury

Aspasia Pefanis iD, Anjan K Bongoni iD, Jennifer L McRae iD, Evelyn J Salvaris iD, Nella Fisicaro iD, James M Murphy iD, Francesco L Ierino iD, Peter J Cowan iD

Biochemical Journal · 2025

DOI: 10.1042/bcj20240569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Journal, 2025. Verfasst von Aspasia Pefanis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Reperfusion Injury, Acute Kidney Injury, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DHAC | National Health and Medical Research Council, Independent Research Institutes Infrastructure Support Scheme, Victoria Government Operational Infrastructure Support Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemia-reperfusion injury (IRI) occurs when the blood supply to an organ is temporarily reduced and then restored. Kidney IRI is a form of acute kidney injury (AKI), which often progresses to kidney fibrosis. Necroptosis is a regulated necrosis pathway that has been implicated in kidney IRI. Necroptotic cell death involves the recruitment of the RIPK1 and RIPK3 kinases and the activation of the terminal effector, the mixed lineage kinase domain-like (MLKL) pseudokinase. Phosphorylated MLKL causes cell death by plasma membrane rupture, driving ‘necroinflammation’. Owing to their apical role in the pathway, RIPK1 and RIPK3 have been implicated in the development of kidney fibrosis. Here, we used a mouse model of unilateral kidney IRI to assess whether the inhibition of RIPK1 or RIPK3 kinase activity reduces AKI and the progression to kidney fibrosis. Mice treated with the RIPK1 inhibitor Nec-1s, either before or after IR, showed reduced kidney injury at 24 hr compared with controls, whereas no protection was offered by the RIPK3 inhibitor GSK´872. In contrast, treatment with either inhibitor from days 3 to 9 post-IR reduced the degree of kidney fibrosis at day 28. These findings further support the role of necroptosis in IRI and provide important validation for the contribution of both RIPK1 and RIPK3 catalytic activities in the progression of kidney fibrosis. Targeting the necroptosis pathway could be a promising therapeutic strategy to mitigate kidney disease following IR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Interacting Protein Serine-Threonine KinasesReperfusion InjuryAcute Kidney InjuryRenal Insufficiency, ChronicProtein Kinase InhibitorsAnimalsMiceMaleMice, Inbred C57BLFibrosisNecroptosisKidneyIndolesImidazoles

Stichwörter der Autor:innen

acute kidney injuryischemia-reperfusionkidney fibrosiskinase inhibitor injuryprogrammed necrosis

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesRipk3 protein, mouseRipk1 protein, mousenecrostatin-1Protein Kinase InhibitorsIndolesImidazoles

Autor:innen und Institutionen

  • Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Nephrology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Australia.
  • Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

ORCID-Profile: Aspasia Pefanis, Anjan K Bongoni, Jennifer L McRae, Evelyn J Salvaris, Nella Fisicaro, James M Murphy, Francesco L Ierino, Peter J Cowan

Förderung

  • DHAC | National Health and Medical Research Council
  • Independent Research Institutes Infrastructure Support Scheme
  • Victoria Government Operational Infrastructure Support Scheme

Zitieren

APA

Pefanis, A., Bongoni, A. K., McRae, J. L., Salvaris, E. J., Fisicaro, N., Murphy, J. M., Ierino, F. L., & Cowan, P. J. (2025). Inhibition of RIPK1 or RIPK3 kinase activity post ischemia-reperfusion reduces the development of chronic kidney injury. Biochemical Journal. https://doi.org/10.1042/bcj20240569

Vancouver

Pefanis A, Bongoni AK, McRae JL, Salvaris EJ, Fisicaro N, Murphy JM, et al. Inhibition of RIPK1 or RIPK3 kinase activity post ischemia-reperfusion reduces the development of chronic kidney injury. Biochemical Journal. 2025. doi:10.1042/bcj20240569

BibTeX
@article{Pefanis2025,
  author = {Pefanis, Aspasia and Bongoni, Anjan K and McRae, Jennifer L and Salvaris, Evelyn J and Fisicaro, Nella and Murphy, James M and Ierino, Francesco L and Cowan, Peter J},
  title = {Inhibition of RIPK1 or RIPK3 kinase activity post ischemia-reperfusion reduces the development of chronic kidney injury},
  journal = {Biochemical Journal},
  year = {2025},
  doi = {10.1042/bcj20240569}
}
Kostenlos starten →